Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Orchestra BioMed Holdings's Revenue for the
three
months ended in Jun. 2026 was $0.09 Mil. Orchestra BioMed Holdings's average Accounts Receivable for the
three
months ended in Jun. 2026 was $0.07 Mil.
Hence, Orchestra BioMed Holdings's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.30.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Orchestra BioMed Holdings Receivables Turnover Related Terms
Orchestra BioMed Holdings Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OBIO vs CYDY, IRD, VNDA: Receivables Turnover Comparison
For the Biotechnology subindustry, Orchestra BioMed Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchestra BioMed Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Orchestra BioMed Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchestra BioMed Holdings (OBIO) has a Receivables Turnover of 1.30 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Orchestra BioMed Holdings and its competitors. According to the industry distribution chart, Orchestra BioMed Holdings ranks #9 out of 853 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Orchestra BioMed Holdings' Receivables Turnover too high?
Orchestra BioMed Holdings' current Receivables Turnover is 1.30. The Biotechnology industry median Receivables Turnover is 5.28. Orchestra BioMed Holdings' value of 1.30 is 75.4% below this industry median. Based on the distribution chart, Orchestra BioMed Holdings ranks #9 out of 853 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Orchestra BioMed Holdings has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orchestra BioMed Holdings' Receivables Turnover compare to CYDY and IRD?
According to the Biotechnology industry distribution chart, Orchestra BioMed Holdings ranks #9 out of 853 companies for Receivables Turnover. This places Orchestra BioMed Holdings in the top 1% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.28. Orchestra BioMed Holdings' value of 1.30 is 75.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchestra BioMed Holdings's current Receivables Turnover of 1.30 is 75.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Orchestra BioMed Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchestra BioMed Holdings's current Receivables Turnover is 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchestra BioMed Holdings stock overvalued right now?
Based on GuruFocus' analysis, Orchestra BioMed Holdings (OBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $31.58, compared to a current price of $5.81 — trading 81.6% below its estimated fair value. The current Receivables Turnover is 1.30 and 75.4% below the Biotechnology industry median of 5.28. Orchestra BioMed Holdings' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Orchestra BioMed Holdings (OBIO), the current Receivables Turnover is 1.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchestra BioMed Holdings (OBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Orchestra BioMed Holdings stock appears to be undervalued.
The current stock price of $5.81 is trading 81.6% below its estimated GF Value™ of $31.58.
GuruFocus considers Orchestra BioMed Holdings to be Possible Value Trap.
Key valuation signals for OBIO:
Receivables Turnover: 1.30
GF Value™: $31.58 vs. price of $5.81 (81.6% below fair value)
Industry Position: 75.4% below the Biotechnology median (#9 of 853)
No single metric tells the full story. See the OBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
42GF Score
Get the complete analysis for OBIO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBIO has been successfully added to your 
